Praxis Medical Insights

Characteristic Features

Individuals with skeletal abnormalities may exhibit disproportionate short stature, genu varum (bowed legs), leg deformities, and fraying and irregularity of growth plates, according to the American Academy of Pediatrics 1

Gradual reintroduction of nutrition with phosphate supplementation and close electrolyte monitoring, especially in the first 72 hours, is recommended for patients at risk of refeeding syndrome, according to the Clinical Nutrition guideline 2, 3, 4
Laboratory monitoring every 6 months is recommended for patients on long-term nutritional supplementation, as suggested by the Clinical Nutrition guideline 2

Hypophosphatemia is a condition that can occur after IV iron therapy, affecting 47-75% of patients, and can persist for up to 6 months in some cases, with the American Journal of Hematology recommending cessation of ferric carboxymaltose (FCM) and treatment of secondary hyperparathyroidism with vitamin D supplementation 5
Hypophosphatemia is defined as serum phosphate levels below the age-related reference range, typically less than 2.5 mg/dL (0.8 mmol/L) in adults, and is classified into four categories:
Category Serum Phosphate Level
Mild <2.5 mg/dL
Moderate 2.0-2.5 mg/dL
Severe 1.0-2.0 mg/dL
Life-threatening <1.0 mg/dL
The American Journal of Hematology recommends checking serum phosphate levels and evaluating for symptoms such as fatigue, proximal muscle weakness, and bone pain, which can mimic iron deficiency anemia, and considering imaging for patients reporting bone pain 5
To rule out other causes, measure serum bicarbonate, urinary calcium, amino acids, glucose, and low-molecular-weight protein markers to exclude metabolic acidosis, hypercalciuria, and renal Fanconi syndrome 6
Evaluate for common causes of hypophosphatemia, such as refeeding syndrome, alcoholism, diabetic ketoacidosis, malnutrition, and medication-induced causes, as well as assessing for secondary causes of erythrocytosis, including arterial blood gas, echocardiogram, and sleep study, as recommended by the American Heart Association, American College of Cardiology, and National Kidney Foundation 5, 8, 6

For mild asymptomatic hypophosphatemia, observation is recommended, and phosphate repletion should be avoided as it can raise parathyroid hormone levels and worsen phosphaturia, ultimately worsening hypophosphatemia, with the American Journal of Hematology recommending monitoring serum phosphate levels until normalization 5
For symptomatic or moderate-to-severe hypophosphatemia, ceasing FCM administration is the most important management step, and treating secondary hyperparathyroidism with vitamin D supplementation is recommended, with consideration of alternative IV iron formulations for future treatments 5
Phosphate supplementation is generally not recommended as it can paradoxically worsen hypophosphatemia by raising PTH and increasing phosphaturia, although vitamin D supplementation before FCM infusion does not prevent hypophosphatemia but may help treat it after it occurs, with the American Journal of Kidney Diseases recommending target phosphorus levels between 2.5-4.5 mg/dL (0.81-1.45 mmol/L) for adults, and 4.0-7.0 mg/dL for children 7, 5
Potassium phosphates are the preferred treatment for hypophosphatemia, except in patients with severe renal impairment, hyperkalemia, or those taking potassium-sparing medications, with the recommended oral dose for mild to moderate hypophosphatemia being 750-1,600 mg elemental phosphorus daily in 2-4 divided doses, as recommended by Clinical Nutrition guidelines 9, 4, 7

Severe hypophosphatemia can cause life-threatening complications, including respiratory muscle weakness, cardiac dysfunction, rhabdomyolysis, altered mental status, and impaired red blood cell function, as stated by the American College of Physicians, with the National Kidney Foundation suggesting monitoring for complications such as hypocalcemia, hyperkalemia, hyperphosphatemia, and nephrocalcinosis when administering phosphate infusions, with a moderate strength of evidence 1, 4
Ensure adequate calcium intake (minimum 1g per day) and recommend a low-sodium diet to reduce calciuria, as suggested by the Nature Reviews Nephrology guidelines, and correct vitamin D deficiency if present, with consideration of active vitamin D (calcitriol 0.50-0.75 μg daily or alfacalcidol 0.75-1.5 μg daily) 1